Abstract:Abstract Background Chronic obstructive pulmonary disease (COPD) receives low awareness and is undertreated in China. Understanding the burden and treatment of COPD across the nation is important for improving quality of care for this disease. This study aims to reveal the current situation of COPD severity distribution and management across China. Methods Baseline data from REALizing and Improving Management of Stable COPD in China, a multicentre, prospective, longitudinal, observational study, were analysed. Patients diagnosed with COPD as per Global Initiative for Chronic Obstructive Lung Disease 2016 (GOLD 2016) criteria were enrolled from 50 randomly selected hospitals (tertiary, 25; secondary, 25) across six geographical regions. Data were collected in routine clinical settings. Results Between 15 December 2017 and 6 August 2020, 5013 patients were enrolled and 4978 included in the full analysis set. Of these, 2459 (49.4%) reported ≥ 1 exacerbation within 12 months prior to study enrolment, with a mean annual rate of 0.9/patient, including 0.2/patient and 0.5/patient leading to emergency room visits and hospitalisation, respectively. Spirometry graded 458 (10.1%), 1886 (41.7%), 1558 (34.5%), and 616 (13.6%) were GOLD stage I–IV, and 536 (11.4%), 1034 (22.0%), 563 (12.0%), and 2566 (54.6%) were classified as GOLD 2016 Group A–D, respectively, without evident regional variations. Inhaled corticosteroids plus long-acting beta 2 -agonist (ICS/LABA, 1316 [26.4%]), ICS/LABA plus long-acting muscarinic antagonist (ICS/LABA + LAMA, 871 [17.5%]), and LAMA (754 [15.1%]) were prescribed at high rates across all groups and regions. Medications not recommended by GOLD were commonly prescribed (TCM, 578 [11.6%]; others, 951 [19.1%]), and 681 (13.7%) were not given ICS or long-acting bronchodilators. Conclusions Disease burden among Chinese COPD outpatients is high. Improved guideline adherence for COPD treatment is needed. Trial registration ClinicalTrials.gov identifier, NCT03131362.

Copd_a_214836 2291..2304

Copd_a_187596 1657..1668

Copd_a_196615 2725..2731

Copd_a_345058 653..665

Copd_a_252097 1287..1299

Cia_a_356925 603..614

Copd_a_234760 397..407

Copd_a_346456 505..515

Copd_a_207023 1769..1778

Copd_a_207855 1933..1941

Copd_a_210598 2015..2025

Ott_a_280535 12163..12168

Ott_a_286600 12777..12786

Nss_a_231456 357..366

An Investigation on Prevention and Treatment of Chronic Obstructive Pulmonary Disease at Two Community Health Service Centers in Urban and Suburban Shanghai

Rmhp_a_328180 4361..4368

Asthma Treatment Adherence and Related Factors in Shanghai, China

Rmhp_a_280672 3067..3077

Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study

Cmar_a_197337 6343..6351

Clinical study on chronic obstructive pulmonary disease diagnosed by spirometry during physical checkup in the community